InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: None

Sunday, 11/20/2016 2:53:01 PM

Sunday, November 20, 2016 2:53:01 PM

Post# of 16885
Zacks hold firm at $12 valuation

They still see $17 million in royalties for 2017 (not including any milestones that might get triggered) and earnings of around a buck a share for 2018.

They are not worried about the slow sales start. Value does not include any ROW value for probuphine, or any value attributable to Parks or T3.

http://s1.q4cdn.com/460208960/files/News/2016/Nov-14-2016_TTNP_Vandermosten.pdf?utm_content=buffer43b00&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

It will be really nice to get some regulatory clarity about the approved 505(b)(2) pathway for Parkinsons once the IND is filed and accepted. I am hoping things will move much quicker ....a combined Phase I/IIA that is followed by a combined Phase IIB/III.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News